Omeros (OMER) Surges on FDA YARTEMLEA Approval: What's Next for 2026?
Omeros (OMER) secured FDA approval for YARTEMLEA (narsoplimab) for TA-TMA, triggering a trading halt and stock surge. We analyze the commercial launch, financial outlook, and key challenges for 2026.